WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing...
WuXi Biologics added to FTSE4Good Index Series for sixth straight year
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
Nomura Raises WUXI BIO TP to HKD51.38, Estimates 1H Profit to Drop 15%
WuXi Biologics schedules board meeting to review interim results
The 2026 Pick-and-Shovel Illusion: Who Is Actually Building the Future?
SDIC Securities Keeps Their Buy Rating on Wuxi Biologics (Cayman) (WXIBF)